The benefit of prothrombin complex concentrate in decreasing neurological deterioration in patients with warfarin-associated intracerebral haemorrhage

被引:0
|
作者
Fong, W. C. [1 ]
Lo, W. T. [1 ]
Ng, Y. W. [1 ]
Cheung, Y. F. [1 ]
Wong, Gordon C. K. [2 ]
Ho, H. F. [2 ]
Chan, John H. M. [1 ]
Li, Patrick C. K. [1 ]
机构
[1] Queen Elizabeth Hosp, Dept Med, Div Neurol, Jordan, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Dept Accid & Emergency, Jordan, Hong Kong, Peoples R China
关键词
INTERNATIONAL NORMALIZED RATIO; FRESH-FROZEN PLASMA; HEMATOMA GROWTH; VITAMIN-K; SAFETY; RECOMMENDATIONS; ENLARGEMENT; GUIDELINES; REVERSAL; UPDATE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare the outcomes of patients with warfarin-associated intracerebral haemorrhage given different treatments to reverse the effect of anticoagulation. Design: Historical cohort study. Setting: A regional hospital in Hong Kong. Patients: Patients on warfarin who developed intracerebral haemorrhage. Interventions: Prothrombin complex concentrate versus fresh frozen plasma treatment. Main outcome measures: The primary outcome measures included the international normalised ratio before and after prothrombin complex concentrate treatment and the neurological deterioration in patients with Glasgow Coma Scale score of more than 8/not intubated/not planned for immediate surgery (target group). Secondary outcome measures were haematoma expansion, 7-day and 30-day mortality rates, and 3-month functional outcome. Safety outcome was the occurrence of a thrombotic event after prothrombin complex concentrate treatment within the index admission. Results: Among 33 patients with clearly documented time of infusion of prothrombin complex concentrate, and whose international normalised ratio was checked before and after prothrombin complex concentrate treatment, the mean international normalised ratio was reduced from 2.81 to 1.21 within 24 hours. Within the target group of patients, there was a significantly lower rate of neurological deterioration in the prothrombin complex concentrate group (17.4% of 23 patients) versus fresh frozen plasma group (45.5% of 33 patients) [P=0.027]. In terms of the 7-day mortality, 30-day mortality, and 3-month functional outcome, prothrombin complex concentrate treated group showed a favourable trend although the difference did not reach a statistical significance. No patient developed thrombotic complications after prothrombin complex concentrate treatment. Conclusions: Prothrombin complex concentrates can reverse the warfarin effect of prolonged international normalised ratio in a timely manner. It might better improve the outcome of warfarin-associated intracerebral haemorrhage compared with fresh frozen plasma treatment by reduction in neurological deterioration.
引用
收藏
页码:486 / 494
页数:9
相关论文
共 50 条
  • [1] PROTHROMBIN COMPLEX CONCENTRATE USE IN WARFARIN-ASSOCIATED INTRACEREBRAL HEMORRHAGE IS NOT ASSOCIATED WITH HIGHER THROMBOEMBOLIC RISKS
    Chou, Sherry
    Konigsberg, Rachael
    Cai, Xuemei
    Bresette, Linda
    Henderson, Galen
    Sorond, Farzaneh
    Ropper, Allan
    Feske, Steven
    CRITICAL CARE MEDICINE, 2009, 37 (12) : A421 - A421
  • [2] Prothrombin complex concentrate administration timing in warfarin-associated intracranial hemorrhage
    Townsend, Brock
    Slechta, Joe
    Gilbert, Brian W.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2024, 76 : 136 - 139
  • [3] ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE OR PLASMA FOR REVERSAL OF WARFARIN-ASSOCIATED COAGULOPATHY
    Rowe, Anthony
    Mahbubani, Pinky
    Bucklin, Mason
    Clark, Christopher
    Hamilton, Leslie
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [4] Activated Prothrombin Complex Concentrate versus Plasma for Reversal of Warfarin-Associated Hemorrhage
    Rowe, Anthony Shaun
    Mahbubani, Pinky S.
    Bucklin, Mason H.
    Clark, Christopher T.
    Hamilton, Leslie A.
    PHARMACOTHERAPY, 2016, 36 (11): : 1132 - 1137
  • [5] Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate
    Peksa, Gary D.
    Mokszycki, Robert K.
    Rech, Megan A.
    Maynard, Brian
    Panos, Nicholas G.
    Sweis, Rolla T.
    DeMott, Joshua M.
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 207 - 215
  • [6] Prothrombin Complex Concentrate (Beriplex P/N)-related Renal and Cerebral Infarctions in a Patient with Warfarin-associated Intracerebral Hemorrhage
    Lin, Shin-Yi
    Tang, Sun-Chun
    Shen, Li-Jiuan
    Jeng, Jiann-Shing
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (01): : E15 - E16
  • [7] Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience
    Maciukaitiene, Jomante
    Bilskiene, Diana
    Tamasauskas, Arimantas
    Bunevicius, Adomas
    MEDICINA-LITHUANIA, 2018, 54 (02):
  • [8] A COMPARISON OF 3-FACTOR PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS IN WARFARIN-ASSOCIATED ICH
    Tucker, Natalie
    Cook, Ryan
    Cave, Brandon
    Jones, Morgan
    CRITICAL CARE MEDICINE, 2020, 48
  • [9] Plasma versus prothrombin complex concentrate for warfarin-associated major bleeding: a systematic review
    Siegal, Deborah M.
    Savage, William J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 448 - 453
  • [10] Uptake of a prothrombin complex concentrate anticoagulation reversal protocol for warfarin-related intracerebral haemorrhage
    Lee, M.
    Geddes, J.
    Hanger, H. C.
    AUSTRALASIAN JOURNAL ON AGEING, 2011, 30 : 16 - 16